What practices ask before they commit

No. Your qualified laboratory team handles daily testing, quality control, documentation, and reporting. Your role is governance and ownership, not bench work.

Some physicians choose to be more involved in the laboratory, and some serve in an oversight role consistent with their qualifications and state rules. The model is designed so that involvement is a choice about governance, not a daily operational requirement.

Not necessarily. Some practices already employ a laboratory manager or medical laboratory scientist who can take on part of the operation. Many do not.

Where there is no qualified staff in place, implementation includes recruiting and placing qualified laboratory leadership and personnel. The laboratory director must meet the CLIA qualifications for the complexity of testing performed, and some states add licensure or qualification requirements of their own.

The practice remains the employer. InHouse Molecular helps define the roles, recruit, and prepare the team, and the launch system includes three months of recruiting support with timing set in the engagement agreement; it does not become the practice's laboratory staff.

Day-to-day operation sits with the practice's employed laboratory personnel, working under qualified laboratory leadership. That includes specimen handling, testing, quality control, instrument maintenance, documentation, and result reporting.

InHouse Molecular designs and builds the operation, prepares the documentation and systems, places qualified laboratory leadership, supports the launch and handoff, and includes three months of recruiting support, with timing specified in the engagement agreement. The practice employs and owns the ongoing laboratory operation.

This distinction is deliberate. If a vendor tells you it will run your laboratory for you, ask who holds the CLIA certificate, who employs the testing personnel, and who is accountable to the surveyor.

Then staffing becomes part of the implementation plan. That can mean recruiting a qualified laboratory director or technical supervisor and testing personnel, or using a qualified contracted leadership arrangement where state and CLIA rules permit it.

Employment and contracting structures have compliance implications, including compensation and referral considerations, and should be reviewed for the specific practice. The assessment is where we establish whether the practice can employ qualified personnel — and it is one of the criteria that determines fit.

Launch ends with an operational handoff: procedures in place, personnel trained and competency-assessed, validation documented, LIS live, billing workflow connected, and the laboratory running under its own leadership. The practice then owns and operates it, employs the staff, and approves its policies and vendor agreements.

The launch system includes three months of recruiting support. Covered roles, the start of that period, and the handoff to the practice's hiring process are defined in the engagement agreement rather than assumed here.

The ongoing relationship can include reagent and extraction-kit supply and support for operational questions within the agreed scope. It does not become a managed service in which an outside party runs the laboratory, and it does not make the laboratory unattended.

A physician office laboratory is a laboratory located in, and operated as part of, a physician practice. This model focuses on infectious-disease testing for the practice's patients, rather than a patient-facing reference laboratory business.

CLIA applies to any facility that tests human specimens to assess health or to diagnose, prevent, or treat disease — including a practice that runs a single test. The certificate type has to match the complexity of the testing performed, and non-waived molecular testing carries quality-system, personnel, proficiency-testing, and documentation obligations that waived testing does not.

An in-house infectious-disease PCR laboratory is therefore a clinical operation with a named laboratory director, qualified personnel, written procedures, and a survey history. It is not an instrument placed in a back room.

Self-operating means the practice owns the capability while qualified laboratory professionals handle daily laboratory operations. It does not mean unattended, automated, or unstaffed testing.

It does not mean unattended, automatic, or free from qualified personnel. The laboratory is staffed by employed laboratory professionals working under qualified laboratory leadership, and it operates inside the practice's clinical and compliance structure.

The phrase describes where the operational burden sits — with the laboratory team, not the physician's schedule — not an absence of human oversight.

The launch system includes fourteen deliverables: Practice readiness assessment; Custom laboratory design; Equipment purchase, delivery, installation, and configuration; Test menu planning; Validation support; SOPs and quality documentation; CLIA and accreditation fees and implementation support; LIS coordination; Billing coordination; Qualified lab director and supervisor placement; Staff recruitment and training; Initial reagents and consumables for the launch menu; Launch-readiness review and operational handoff; Three months of recruiting support.

The implementation fee includes the equipment in the approved launch scope, delivery, installation, and configuration, agreed CLIA and accreditation fees, initial reagents and consumables for the launch menu, and the implementation work required to prepare the laboratory for launch.

Billing coordination means the laboratory's billing workflow is set up and connected to the practice's billing process; coding, payer contracts, and reimbursement decisions stay with the practice. Staffing support means the roles are defined, candidates are sourced, and the team is trained, with a three-month recruiting-support period set out in the engagement agreement.

What does not change: the practice employs the laboratory personnel, owns the operation, approves its policies and vendor agreements, and holds the CLIA certificate. InHouse Molecular designs and builds the operation and prepares it for handoff; it does not operate the laboratory on the practice's behalf.

Your practice provides the space, employs the laboratory team, approves the final configuration, and handles ongoing operating expenses after launch. It also holds the CLIA certificate and any state license, approves the policies and vendor agreements it signs, and makes the clinical decisions about the test menu.

After handoff, the practice operates the laboratory, maintains compliance, and manages billing and reimbursement for the testing it performs. Equipment, installation, agreed CLIA and accreditation fees, and initial launch supplies are included in the implementation fee rather than purchased separately.

Yes. The Practice Feasibility Review is a paid assessment. Request the current review price and terms when you submit your practice profile.

Submitting the profile does not purchase an assessment or authorize a payment. This website form does not collect payment.

There is no single answer, because the requirement depends on the test menu, specimen volume, instrument footprint, storage for reagents and supplies, waste handling, and the practice's existing layout.

The assessment reviews a dedicated room or appropriately separated area, including benching, storage, specimen flow, safety, and equipment requirements. The necessary footprint is specific to the proposed operation.

Space is assessed during the practice assessment. No credible party can give a square-footage number before reviewing the menu, volume, and floor plan.

Timing depends on state licensure and CLIA processing, equipment lead times, space readiness, validation, and how quickly qualified personnel can be hired. A realistic sequence is developed only after these dependencies have been reviewed.

We do not quote a guaranteed timeline. The sequence is planned during the assessment, and each dependency is tracked so the practice knows what is waiting on what.

CLIA is federal, but states add their own laboratory licensure or registration requirements, personnel licensure rules, and inspection practices. Washington and New York operate state programs that substitute for federal CLIA, with their own application paths.

Those differences affect the application sequence, the documentation required, and how long approval takes. They are one reason a build plan that worked in one state cannot simply be copied into another.

Implementation includes LIS selection and configuration support, order-to-result workflow, result reporting, and downtime procedures. Where an EHR interface is required, the practice's EHR vendor is usually a necessary participant and should be planned for early.

The practice approves the configuration and owns the system relationship. Our role is to make sure the workflow matches how the laboratory will actually operate, including specimen accessioning, result review, and documentation.

Before patient testing, the laboratory verifies or establishes performance specifications for each method — accuracy, precision, reportable range, and reference intervals — according to CLIA requirements and the manufacturer's instructions.

Validation produces the records a surveyor will ask for, and it is also where staff learn the assay. Personnel are trained and competency-assessed before they test patient specimens, and the documentation is retained with the laboratory's records.

The implementation fee includes agreed CLIA and accreditation fees. The CLIA process includes identifying the correct certificate type for the intended complexity, preparing the application and supporting documentation, structuring quality control and proficiency testing, and getting the laboratory survey-ready.

The practice holds the certificate and remains the regulated entity. InHouse Molecular supports the implementation; it does not approve, certify, or guarantee a CLIA outcome.

The implementation fee includes the equipment in the approved launch scope, delivery, installation, and configuration; agreed CLIA and accreditation fees; initial reagents and consumables for the launch menu; and the implementation work required to prepare the laboratory for launch.

Your practice provides the space, employs the laboratory team, approves the final configuration, and handles ongoing operating expenses after launch.

The menu is chosen for the practice's patient population, clinical need, volume, and payer realities. Common categories include respiratory and mini respiratory panels, urinary tract infection and antibiotic-resistance markers, sexually transmitted infection, HPV, women's health, gastrointestinal, wound, dermatology, and nail testing.

The specific assays depend on the platform selected, the manufacturer's intended use, and the practice's own validation. Each method must be validated by the laboratory before it is used for patient care, and the menu can be phased as volume and confidence grow.

InHouse Molecular supports laboratory implementation, but healthcare ownership, compensation, referral, billing, reimbursement, and fraud-and-abuse structures must be evaluated for the specific practice and reviewed with qualified healthcare counsel where appropriate. No reimbursement, profit, or legal outcome is guaranteed.

In practice, the structure has to be evaluated for the specific practice: who owns the laboratory, how the practice is organized, how the laboratory is compensated, how testing is billed, and how referrals within the practice work. Arrangements that are common in one specialty or state are not automatically available in another.

We support implementation and can explain the operational model. We do not provide legal advice, and we do not treat a compliance conclusion as part of the build.

No. Coverage, medical necessity, coding, payer contracts, and patient responsibility all affect what is paid, and those rules vary by payer and by state.

Any model that promises reimbursement outcomes is describing something it cannot control. The assessment looks at the practice's payer mix and testing patterns so the practice can evaluate the economics with real information.

No. Laboratory economics depend on volume, payer mix, staffing cost, reagent and equipment cost, and how much testing is clinically appropriate for the practice's patients.

We do not publish revenue projections, reimbursement percentages, or profit figures for a practice we have not assessed, and we do not present the laboratory as a passive-income opportunity. The point of the model is clinical control and operational fit; the financial result follows from the practice's own situation.

Often, yes — subject to platform compatibility, the practice's existing validated methods, and its certification status. A laboratory that already runs molecular testing may need less build support and more supply continuity.

We would still review the current operation before supplying reagents, because the reagents have to match the platform and the validation record, not the other way around.